ArticleCancer innovation2022
Pyrotinib-associated acute kidney injury: A case report.
Article in Cancer innovation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Pyrotinib-associated acute kidney injury: A case report.Cancer innovation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyrotinib is a novel human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI). Previous studies of pyrotinib showed that it is mainly excreted through the gastrointestinal tract rather than the kidneys, with little effect on renal function. Here, we report a patient with HER2-mutated nonsmall cell lung cancer who developed acute kidney injury (AKI) after receiving pyrotinib treatment. This case alerts clinicians to the adverse renal effects of HER2 TKIs, especially in patients with chronic kidney disease. However, tumor treatment should remain a priority in clinical practice. In this case, AKI induced by pyrotinib was reversible. Therefore, there is no need to restrict the use of HER2 TKIs due to concerns about possible nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.